Similarly, the loss of neurofibromin 1 (NF1) observed in BRAF mutant tumour cells leads to intrinsic resistance through the loss of NF1 inhibition of RAS and MAPK signalling [32,37,66]. The gene discussed is BRAF; the disease is neoplasm.